NCT02663518 2024-05-10A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid TumorsPfizerPhase 1 Terminated249 enrolled 43 charts
NCT03878524 2024-03-04Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialOHSU Knight Cancer InstitutePhase 1 Terminated2 enrolled
NCT03436862 2023-12-05Nivolumab Maintenance Therapy After Autologous Stem Cell Transplant in Hodgkin Lymphoma Pts at Relapse/Progression RiskSCRI Development Innovations, LLCPhase 2 Completed37 enrolled 6 charts
NCT01822509 2021-06-24Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell TransplantNational Cancer Institute (NCI)Phase 1 Completed71 enrolled